Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Last Published 07.01.2026 Effective Date: 07.01.2026 This policy addresses the use of Tysabri (natalizumab) for the treatment of relapsing forms of multiple sclerosis and Crohn's disease
Key stat: 63% of millennials and 61% of Gen Zers feel more connected to health brands since starting GLP-1s, per a January Dentsu report
In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]
The threshold for this year is $821 million
For context, existing FDA-approved medications for alcohol use disorder, like naltrexone and acamprosate, typically show reductions in the range of 15 to 25%